Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines. It expects $1.5 billion to $2.5 billion in annual revenue,
Moderna shares plunge after company cuts vaccine sales outlook
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading.
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
Moderna shares plunge as company dramatically lowers sales forecast
Axios Visuals Moderna shares plunged today to lows not seen since the early weeks of the pandemic after the company dramatically lowered its sales forecast. Zoom in: Waning demand for COVID vaccines is crushing Moderna's revenue.
Moderna Cuts 2025 Revenue Forecast by $1 Billion, Shares Drop 17% As Investors Eye $30 Support Level
Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced plans to cut $1.5 billion in expenses this year. The company faces challenges balancing rising drug development costs with declining demand for Covid-19 treatments and slow adoption of its RSV medication.
Moderna's Road To Stopping The Red
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
FiercePharma8d
After tough year, Moderna CEO confronts challenges for RSV, COVID businesses in shareholder letter
With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
FiercePharma2d
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%
Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death ...
Moderna price target lowered to $38 from $70 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...